7.1 Muscle-Invasive Bladder Cancer (MIBC) Staging & Neoadjuvant Therapy

7.1 Muscle-Invasive Bladder Cancer (MIBC) Staging & Neoadjuvant Therapy

Muscle-invasive bladder cancer (MIBC) accounts for approximately 20% to 25% of all newly diagnosed bladder tumors and carries an aggressive natural history with a high propensity for early occult micrometastatic dissemination. Optimal management requires precise pathological characterization, systematic cross-sectional clinical staging, and timely integration of multimodality systemic therapy prior to definitive local extirpation or radiation-based bladder preservation.

---

1. Clinical Presentation & Initial Assessment

The most common presenting symptom is painless macroscopic (gross) hematuria. Other primary clinical manifestations include:

• Irritable Lower Urinary Tract Symptoms (LUTS): Persistent urgency, frequency, and dysuria in the absence of documented bacterial infection, frequently reflecting extensive trigonal involvement, malignant detrusor irritability, or accompanying diffuse carcinoma in situ (CIS).
• Ureteral Obstruction & Flank Pain: Hydroureteronephrosis resulting from tumor infiltration or compression of the intramural ureteric orifice.
• Pelvic Symptoms & Mass: Deep aching pelvic or perineal discomfort, lower extremity lymphedema, or a palpable pelvic mass, indicating advanced extravesical extension or extensive pelvic sidewall nodal involvement.

Bimanual Examination Under Anesthesia (EUA)

A structured bimanual examination (one hand on the lower abdomen, index finger in the rectum for men or vagina for women) under full neuromuscular blockade before and after transurethral resection remains a cornerstone of physical staging:

• No palpable mass: Compatible with organ-confined disease, but does not exclude extravesical invasion; T3a is microscopic extension beyond the bladder.
• Palpable, mobile three-dimensional mass: Suggests macroscopic extravesical invasion (cT3b).
• Fixed pelvic mass: Raises concern for pelvic/abdominal wall invasion (cT4b). EUA can under- or overstage disease; interpret it with pathology and imaging.

---

2. TNM Staging Classification (UICC 9th Edition, 2025)

Current EAU guidance uses the UICC 9th edition; the principal bladder T, N and M categories below are retained from the 8th edition:

Primary Tumour (T Stage)

• T2: Tumor invades the detrusor muscle (muscularis propria).
  • T2a: Tumor invades the inner (superficial) half of the muscularis propria.
  • T2b: Tumor invades the outer (deep) half of the muscularis propria.
• T3: Tumor invades perivesical tissue (extravesical extension).
  • T3a: Microscopically invades perivesical tissue.
  • T3b: Macroscopically invades perivesical tissue (extravesical mass visible on imaging or EUA).
• T4: Tumor invades adjacent structures.
  • T4a: Tumor directly invades the prostatic stroma, seminal vesicles, uterus, or vagina.
  • T4b: Tumor directly invades the pelvic wall or abdominal wall.

Regional Lymph Nodes (N Stage)

Regional lymph nodes include the true pelvic nodes (internal iliac/hypogastric, external iliac, obturator and presacral) and common iliac nodes:

• N0: No regional lymph node metastasis.
• N1: Metastasis in a single regional lymph node in the true pelvis.
• N2: Metastasis in multiple regional lymph nodes in the true pelvis.
• N3: Metastasis in common iliac lymph node(s).

Distant Metastasis (M Stage)

• M0: No distant metastasis.
• M1a: Metastasis in any non-regional lymph nodes, such as para-aortic, paracaval, inguinal, mediastinal or supraclavicular nodes; common iliac nodes remain regional (N3).
• M1b: Non-lymph node distant metastasis (visceral metastases: lungs, liver, bones, peritoneum, or pleura).

---

3. Cross-Sectional Diagnostic & Staging Modalities

Accurate staging determines whether a patient is a candidate for curative-intent surgery, neoadjuvant therapy, or palliative systemic interventions.

Contrast-Enhanced Computed Tomography (CECT)

• Standard of Care: CT of the chest, abdomen and pelvis is used for MIBC staging, with appropriate contrast/urographic phases to assess abdominal organs and the upper urinary tract.
• Thoracic Imaging: Chest CT assesses pulmonary metastases more sensitively than chest radiography. Triphasic acquisition of the chest itself is not required.
• Abdominal and Pelvic Imaging: Evaluates the depth of primary tumor infiltration, retroperitoneal and pelvic lymphadenopathy (short-axis lymph node diameter >8 mm in the pelvis or >10 mm in the retroperitoneum is suspicious for metastasis), hepatic metastases, and synchronous upper tract urothelial carcinoma (UTUC).

Pelvic Multiparametric MRI & VI-RADS

Multiparametric MRI (mpMRI) using T2-weighted, diffusion-weighted (DWI), and dynamic contrast-enhanced (DCE) imaging demonstrates superior soft-tissue contrast compared to CT:

• VI-RADS (Vesical Imaging-Reporting and Data System): A standardized 5-point scoring system assessing the structural integrity of the low-signal-intensity muscularis propria on T2-weighted imaging and high-signal restriction on DWI.
• Diagnostic Accuracy: EAU cites pooled mpMRI/VI-RADS sensitivity of 83% and specificity of 90% for predicting muscle invasion, with performance dependent on the threshold and setting. If MRI is used for primary local staging, perform it before TURBT. MRI does not replace adequate histological staging or indicated repeat TURBT.

[18F]FDG Positron Emission Tomography / CT (PET/CT)

Urinary FDG excretion limits assessment of the primary bladder tumour. FDG-PET/CT can reveal additional nodal or distant disease in selected patients, but nodal sensitivity is limited despite relatively high specificity: a negative scan cannot exclude microscopic metastases. It supplements rather than replaces standard staging. Routine bone scanning is unnecessary without clinical suspicion of skeletal spread.

---

4. Neoadjuvant & Perioperative Systemic Therapy

Level 1 Evidence & The Evolution of Perioperative Therapy

Randomized controlled trials and the definitive Advanced Bladder Cancer (ABC) Meta-analysis established neoadjuvant cisplatin-based combination chemotherapy as conferring a proven survival advantage:

• Overall Survival Benefit: The ABC individual-patient meta-analysis found a 5 percentage-point five-year OS benefit from platinum-based combination NAC (HR 0.86); a later analysis cited by EAU found an 8 percentage-point benefit.
• Number Needed to Treat (NNT): At five years, $1/0.05=20$ or $1/0.08=12.5$ (approximately 13 patients), depending on the absolute benefit used. Do not combine one analysis's HR with another's absolute result.
• Pathological Downstaging: pCR (ypT0N0) is a favourable prognostic finding. In SWOG 8710, no residual bladder tumour was found in 38% versus 15% after neoadjuvant MVAC versus surgery alone; five-year survival in the MVAC pT0 subgroup was 85%, a trial result rather than a universal forecast.

The New Standard of Care: Perioperative Chemoimmunotherapy (NIAGARA Regimen)

The landmark phase III NIAGARA trial demonstrated that adding immune checkpoint inhibition to cisplatin-based chemotherapy across the perioperative period significantly improves oncological outcomes compared to neoadjuvant chemotherapy alone:

• Regimen Architecture:
  • Neoadjuvant Phase: Gemcitabine (1000 mg/m² IV on days 1 and 8) plus cisplatin (70 mg/m² IV on day 1, or split into 35 mg/m² on days 1 and 8) administered concurrently with durvalumab (1500 mg IV on day 1) every 3 weeks for 4 cycles.
  • Surgical Extirpation: Radical cystectomy with bilateral standard pelvic lymphadenectomy after recovery from neoadjuvant therapy, avoiding unnecessary delay.
  • Adjuvant Phase: Continuation of durvalumab (1500 mg IV every 4 weeks) for 8 cycles post-operatively.
• Trial Outcomes:
  • Statistically significant improvement in event-free survival (EFS): Hazard ratio 0.68 (95% CI 0.56–0.82, p < 0.001).
  • Statistically significant improvement in overall survival (OS): Hazard ratio 0.75 (95% CI 0.59–0.93, p = 0.01).
  • An updated pathological complete response analysis found 37.3% versus 27.5%; the original formal pCR endpoint did not meet its prespecified significance threshold. EFS and OS established the benefit.
• Guideline Status: Approved by the EMA and FDA, current EAU Guidelines (2025/2026 Update) assign a Strong Recommendation to offer perioperative chemoimmunotherapy with cisplatin/gemcitabine and durvalumab (NIAGARA regimen) to patients with MIBC (cT2–T4a, cN0–1 M0) who are eligible for cisplatin-based chemotherapy and immunotherapy.
• Expanded Renal Eligibility: NIAGARA and current EAU perioperative guidance allow GFR $\ge$ 40 mL/min, with cisplatin 35 mg/m² on days 1 and 8 for the 40–59 mL/min group. Assess other fitness criteria and confirm borderline renal estimates; GFR alone does not establish eligibility.

Alternative Cisplatin Regimens (When Immunotherapy is Contraindicated)

When immune checkpoint inhibitors are contraindicated (e.g., severe active autoimmune disorders):

1. Dose-Dense MVAC (ddMVAC): Methotrexate, vinblastine, doxorubicin and cisplatin every two weeks with G-CSF support. VESPER compared six ddMVAC cycles with four GC cycles. The overall perioperative three-year PFS comparison (64% versus 56%, p=0.066) did not meet the primary endpoint. In the neoadjuvant subgroup, three-year PFS was 66% versus 56% (HR 0.70, p=0.025); five-year OS was 66% versus 57% (HR 0.71).
2. Gemcitabine plus Cisplatin (GC): Gemcitabine on days 1 and 8 plus cisplatin on day 1 (or split days 1 and 8), every 21 days for four cycles. GC remains an accepted NAC regimen. Its favourable toxicity comparison with conventional MVAC in advanced disease does not establish equivalence to six-cycle neoadjuvant ddMVAC.

Timing & Delay Restrictions

Organise cystectomy promptly once the patient has recovered from NAC. EAU advises avoiding delays beyond three months when neoadjuvant treatment is not being given. A planned NAC course is not a breach of that diagnosis-to-surgery rule; avoid unnecessary delays after its completion.

---

5. Cisplatin Eligibility & Systemic Regimens for Ineligible Patients

Cisplatin is an active, nephrotoxic, neurotoxic and emetogenic platinum agent that crosslinks DNA. The 2011 Galsky consensus defined cisplatin ineligibility for metastatic urothelial carcinoma; perioperative protocols may use different renal thresholds.

Updated Assessment of Cisplatin Eligibility

A patient is traditionally classified as ineligible for cisplatin if they exhibit ANY ONE of the following physiological parameters:

1. Renal Function: Creatinine clearance < 60 mL/min in the classical consensus.
   • Contemporary Practice & Protocol Modification: NIAGARA allowed GFR $\ge$ 40 mL/min, using split-dose cisplatin (35 mg/m² on days 1 and 8) at 40–59 mL/min. Below 40 mL/min the patient falls outside that regimen's renal eligibility; do not extrapolate it as a universal safety guarantee or ignore hearing, neuropathy, cardiac and performance-status assessment.
2. Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status $\ge$ 2 (or Karnofsky Performance Scale $\le$ 70%).
3. Audiometric Impairment: Documented CTCAE grade $\ge$ 2 hearing loss. Grade 2 can occur without a hearing-aid requirement; assess audiometry and functional impact rather than equating grade 2 with grade 3 hearing loss.
4. Peripheral Neuropathy: Grade $\ge$ 2 peripheral neuropathy (sensory loss or paresthesias interfering with ADLs).
5. Congestive Heart Failure: New York Heart Association (NYHA) functional class $\ge$ III (marked limitation of physical activity, comfort only at rest; unable to tolerate intensive pre- and post-cisplatin intravenous hydration).

Systemic Therapy for Cisplatin-Ineligible Patients: Perioperative EV + Pembrolizumab

Historically, cisplatin-ineligible patients with localized MIBC were offered no neoadjuvant systemic therapy and were directed straight to upfront radical cystectomy. This historical paradigm has been overturned by landmark phase III trial evidence:

• The KEYNOTE-905 / EV-303 Phase III Trial:
  • Evaluated perioperative enfortumab vedotin (EV)—an antibody-drug conjugate (ADC) targeting cell-surface Nectin-4 linked to the microtubule-disrupting cytotoxin monomethyl auristatin E (MMAE)—in combination with pembrolizumab (anti-PD-1 checkpoint inhibitor) in surgery-eligible patients with cT2–T4aN0M0 or cT1–T4aN1M0 predominant urothelial cancer who were cisplatin-ineligible or declined cisplatin.
  • Regimen: Three 21-day neoadjuvant cycles (EV on days 1 and 8, pembrolizumab on day 1), then cystectomy with PLND. Postoperatively give six EV cycles and fourteen pembrolizumab cycles every three weeks: pembrolizumab continues alone after EV finishes.
  • Outcomes: pCR was 57.1% versus 8.6%, with EFS HR 0.40 and OS HR 0.50 versus surgery followed by observation. These results support the perioperative option for appropriate cisplatin-ineligible patients.
• EAU Guideline Recommendation (2025/2026 Update):
  • Strong Recommendation: Offer perioperative enfortumab vedotin plus pembrolizumab to patients with MIBC who are ineligible for cisplatin-based chemotherapy, rather than routine upfront cystectomy without consideration of systemic therapy.

Why Carboplatin Is Not Recommended as NAC

Role of Upfront Radical Cystectomy

Upfront radical cystectomy with bilateral standard pelvic lymphadenectomy remains appropriate when the MDT judges perioperative systemic treatment unsuitable or it is declined, for example:

1. Patients who are unfit for both cisplatin and enfortumab vedotin plus pembrolizumab (e.g., severe uncontrolled autoimmune disease, severe pre-existing peripheral neuropathy, uncontrolled poorly managed diabetes precluding EV, or ECOG performance status $\ge$ 3).
2. Patients who decline perioperative systemic therapy.

Adjuvant Immunotherapy for High-Risk Pathological Disease

After surgery without neoadjuvant systemic therapy, offer cisplatin-based adjuvant combination chemotherapy to fit patients with pT3/4 and/or pN+ disease. For patients unsuitable for or declining adjuvant cisplatin, discuss one year of nivolumab for high-risk disease: pT3/4 and/or pN+ without NAC, or $\ge$ ypT2N0/ypN+ after NAC. CheckMate 274 improved DFS versus placebo in the overall and PD-L1-positive populations. EU authorisation requires tumour-cell PD-L1 $\ge$ 1%; FDA approval does not. Do not automatically add nivolumab to an already planned perioperative checkpoint-inhibitor regimen.

---

6. Trimodal Therapy (TMT) for Bladder Preservation

Trimodal therapy (TMT) represents an evidence-based, oncologically valid alternative to radical cystectomy for carefully selected patients who prioritize bladder preservation or possess prohibitive surgical comorbidities.

The Three Components of TMT

1. Maximal TURBT: Resect as much visible tumour as safely possible, ideally achieving complete macroscopic clearance. A TURBT does not certify the circumferential surgical margins of a cystectomy specimen.
2. Radiosensitizing Chemotherapy: Concurrent administration of radiosensitizing chemotherapeutic agents—typically cisplatin plus 5-fluorouracil (5-FU), mitomycin C plus 5-FU (BC2001 trial protocol), or weekly low-dose cisplatin.
3. External Beam Radiotherapy (EBRT): Conventional treatment gives 40–45 Gy initially and a boost to 60–66 Gy to the bladder/tumour bed. Elective pelvic nodal irradiation is optional in cN0 disease. 55 Gy in 20 fractions is an accepted bladder-only alternative.

Candidate Selection Criteria

Selection strongly influences outcome; local response, bladder-intact survival and overall survival are different endpoints. Favourable features include:

• Solitary / Unifocal Tumor: Usually cT2–T3a, with a smaller, completely resectable tumour most favourable.
• No or Unilateral Hydronephrosis: Hydronephrosis is an adverse feature; selected unilateral cases remain candidates, whereas bilateral obstruction is less favourable.
• Absence of Extensive Carcinoma in Situ (CIS): Extensive or multifocal CIS increases the risk of urothelial recurrence and makes bladder preservation less favourable.
• Good Baseline Bladder Function & Capacity: Normal functional capacity without severe baseline urge incontinence, small-capacity spastic bladder, or severe refractory LUTS.
• Completeness of Initial Resection: Complete macroscopic clearance achieved at the preliminary TURBT.

Split-Course vs Continuous Protocols & Salvage Cystectomy

• Historical split-course regimens reassess response with cystoscopy/biopsy after induction chemoradiation; complete responders proceed to consolidation. Continuous-course treatment is now standard, with response assessment after completion.
• Persistent or recurrent muscle-invasive disease requires prompt evaluation for salvage cystectomy in fit patients. Selected non-muscle-invasive recurrences may instead be managed with TURBT and appropriate intravesical treatment.
• All TMT patients need lifelong bladder surveillance; a clinical complete response is not a cystectomy-proven pathological response.

---

7. Staging and Decision-Making Pathways

Contemporary Physiological Stratification for Systemic Therapy

Multimodality Management Pathway for cT2–T4aN0M0 MIBC